The myocardial JAK/STAT pathway: From protection to failure

Pharmacology and Therapeutics

Volumn 120, Issue 2, 2008, Pages 172-185

  Boengler, Kerstin ^a   Hilfiker Kleiner, Denise ^b   Drexler, Helmut ^b   Heusch, Gerd ^a   Schulz, Rainer ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Aging; Hypertrophy; Ischemia; JAK STAT; Mitochondria; Postconditioning; Preconditioning; Reperfusion; Signal transducer and activator of transcription

Indexed keywords

INTERLEUKIN 6; JANUS KINASE; STAT3 PROTEIN;

AGING; CELL NUCLEUS; DNA MODIFICATION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; MITOCHONDRION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REPERFUSION INJURY; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-6; JANUS KINASES; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STRESS, PHYSIOLOGICAL; TRANSCRIPTION, GENETIC;

EID: 53749100817     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.08.002     Document Type: Review

References (201)

1. Abe Y., Ono K., Kawamura T., Wada H., Kita T., Shimatsu A., and Hasegawa K. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 292 (2007) H2387-H2396
2. Akimoto T., Numata F., Tamura M., Takata Y., Higashida N., Takashi T., Takeda K., and Akira S. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 187 (1998) 1537-1542
3. Albright J.W., Bream J.H., Bere E.W., Young H.A., Winkler-Pickett R., and Ortaldo J.R. Aging of innate immunity: functional comparisons of NK/LAK cells obtained from bulk cultures of young and aged mouse spleen cells in high concentrations of interleukin-2. Exp Gerontol 39 (2004) 73-82
4. Aoyama T., Takimoto Y., Pennica D., Inoue R., Shinoda E., Hattori R., Yui Y., and Sasayama S. Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. J Mol Cell Cardiol 32 (2000) 1821-1830
5. Bader A., Al-Dubai H., and Weitzer G. Leukemia inhibitory factor modulates cardiogenesis in embryoid bodies in opposite fashions. Circ Res 86 (2000) 787-794
6. Baines C.P., Goto M., and Downey J.M. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 29 (1997) 207-216
7. Barry S.P., Townsend P.A., Latchman D.S., and Stephanou A. Role of the JAK-STAT pathway in myocardial injury. Trends Mol Med 13 (2007) 82-89
8. Bartoli M., Gu X.L., Tsai N.T., Venema R.C., Brooks S.E., Marrero M.B., and Caldwell R.B. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem 275 (2000) 33189-33192
9. Bell R.M., Cave A.C., Johar S., Hearse D.J., Shah A.M., and Shattock M.J. Pivotal role of NOX-2-containing NADPH oxidase in early ischemic preconditoning. FASEB J 19 (2005) 2037-2039
10. Berry M.F., Pirolli T.J., Jayasankar V., Morine K.J., Moise M.A., Fisher O., Gardner T.J., Patterson P.H., and Woo Y.J. Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure. J Thorac Cardiovasc Surg 128 (2004) 866-875
11. Boengler K., Konietzka I., Buechert A., Heinen Y., Garcia-Dorado D., Heusch G., and Schulz R. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 292 (2007) H1764-H1769
12. Boengler K., Buechert A., Heinen Y., Roeskes C., Hilfiker-Kleiner D., Heusch G., and Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102 (2008) 131-135
13. Boengler K., Konietzka I., van de Sand A., Hilfiker-Kleiner D., Heusch G., and Schulz R. Signal transducer and activator of transcription is located in the matrix of cardiomyocyte mitochondria. J Mol Cell Cardiol 44 (2008) 762 (abstr)
14. Bolli R., Manchikalapudi S., Tang X.L., Takano H., Qiu Y., Guo Y., Zhang Q., and Jadoon A.K. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Circ Res 81 (1997) 1094-1107
15. Bolli R., Dawn B., and Xuan Y.T. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 13 (2003) 72-79
16. Booz G.W., Day J.N.E., and Baker K.M. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34 (2002) 1443-1453
17. Buettner R., Mora L.B., and Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Canc Res 8 (2002) 945-954
18. Burke W.M., Jin X.H., Lin H.J., Huang M., Liu R., Reynolds R.K., and Lin J.Y. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20 (2001) 7925-7934
19. Buttmann M., Berberich-Siebelt F., Serfling E., and Rieckmann P. Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells. J Vasc Res 44 (2007) 51-60
20. Caldenhoven E., vanDijk T.B., Solari R., Armstrong J., Raaijmakers J.A.M., Lammers J.W.J., Koenderman L., and deGroot R.P. STAT3 beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 271 (1996) 13221-13227
21. Chandrasekar B., Mitchell D.H., Colston J.T., and Freeman G.L. Regulation of CCAAT/enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion. Circulation 99 (1999) 427-433
22. Chen L.M., Kuo W.W., Yang J.J., Wang S.G.P., Yeh Y.L., Tsai F.J., Ho Y.J., Chang M.H., Huang C.Y., and Lee S.D. Eccentric cardiac hypertrophy was induced by long-term intermittent hypoxia in rats. Exp Physiol 92 (2007) 409-416
23. Cohen M.V., and Downey J.M. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103 (2008) 203-215
24. Cooney R.N. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock 17 (2002) 83-90
25. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
26. Das D.K., Maulik N., Sato M., and Ray P.S. Reactive oxygen species function as second messenger during ischemic preconditioning of heart. Mol Cell Biochem 196 (1999) 59-67
27. Dawn B., Xuan Y.T., Guo Y., Rezazadeh A., Stein A.B., Hunt G., Wu W.J., Tan W., and Bolli R. Il-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64 (2004) 61-71
28. De-Fraja C., Conti L., Govoni S., Battaini F., and Cattaneo E. STAT signalling in the mature and aging brain. Int J Dev Neurosci 18 (2000) 439-446
29. Downey J.M., Krieg T., and Cohen M.V. Mapping preconditioning's signaling pathways: an engineering approach. Ann N Y Acad Sci 1123 (2008) 187-196
30. Dumler I., Kopmann A., Wagner K., Mayboroda O.A., Jerke U., Dietz R., Haller H., and Gulba D.C. Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J Biol Chem 274 (1999) 24059-24065
31. Durbin J.E., Hackenmiller R., Simon M.C., and Levy D.E. Targeted disruption of the mouse STAT1 results in compromised innate immunity to viral disease. Cell 84 (1996) 443-450
32. Eghbali M., Deva R., Alioua A., Minosyan T.Y., Ruan H.M., Wang Y.B., Toro L., and Stefani E. Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96 (2005) 1208-1216
33. Ehret G.B., Reichenbach P., Schindler U., Horvath C.M., Fritz S., Nabholz M., and Bucher P. DNA binding specificity of different STAT proteins - comparison of in vitro specificity with natural target sites. J Biol Chem 276 (2001) 6675-6688
34. Eiken H.G., Oie E., Damas J.K., Yndestad A., Bjerkeli V., Aass H., Simonsen S., Geiran O.R., Tonnessen T., Christensen G., Froland S.S., Gullestad L., Attramadal H., and Aukrust P. Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest 31 (2001) 389-397
35. Ferdinandy P., Schulz R., and Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59 (2007) 418-458
36. Fischer P., and Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Res Cardiol 102 (2007) 279-297
37. Florholmen G., Aas V., Rustan A.C., Lunde P.K., Straumann N., Eid H., Odegaard A., Dishington H., Andersson K.B., and Christensen G. Leukemia inhibitory factor reduces contractile function and induces alterations in energy metabolism in isolated cardiomyocytes. J Mol Cell Cardiol 37 (2004) 1183-1193
38. Forbes R.A., Steenbergen C., and Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 88 (2001) 802-809
39. Foshay K., Rodriguez G., Hoel B., Narayan J., and Gallicano G.I. JAK2/STAT3 directs cardiomyogenesis within murine embryonic stem cells in vitro. Stem Cells 23 (2005) 530-543
40. Frias M.A., Rebsamen M.C., Gerber-Wicht C., and Lang U. Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: a role in cardiac hypertrophy. Cardiovasc Res 73 (2007) 57-65
41. Fuchs M., Hilfiker A., Kaminski K., Hilfiker-Kleiner D., Guener Z., Klein G., Podewski E., Schieffer B., Rose-John S., and Drexler H. Role of interleukin-6 for left ventricular remodeling and survival after experimental myocardial infarction. FASEB J 17 (2003) 2118-2120
42. Fuglesteg B.N., Suleman N., Tiron C., Kanhema T., Lacerda L., Andreasen T.V., Sack M.N., Jonassen A.K., Mjos O.D., Opie L.H., and Lecour S. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol (2008) 10.1007/s00395-008-0728-x
43. Fujio Y., Kunisada K., Hirota H., YamauchiTakihara K., and Kishimoto T. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J Clin Invest 99 (1997) 2898-2905
44. Fukuzawa J., Booz G.W., Hunt R.A., Shimizu N., Karoor V., Baker K.M., and Dostal D.E. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3 - an autocrine loop for hypertrophy. Hypertension 35 (2000) 1191-1196
45. Gabriel B., Sureau F., Casselyn M., Teissie J., and Petit P.X. Retroactive pathway involving mitochondria in electroloaded cytochrome c-induced apoptosis protective properties of Bcl-2 and Bcl-(XL). Exp Cell Res 289 (2003) 195-210
46. Gariboldi M.B., Ravizza R., Molteni R., Osella D., Gabano E., and Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 258 (2007) 181-188
47. Gross E.R., Hsu A.K., and Gross G.J. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3ß. Am J Physiol Heart Circ Physiol 291 (2006) H827-H834
48. Gross E.R., Hsu A.K., and Gross G.J. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3 beta. Diabetes 56 (2007) 127-136
49. Guaiquil V.H., Golde D.W., Beckles D.L., Mascareno E.J., and Siddiqui M.A.Q. Vitamin C inhibits hypoxia-induced damage and apoptotic signaling pathways in cardiomyocytes and ischemic hearts. Free Radic Biol Med 37 (2004) 1419-1429
50. Guo Y., Jones W.K., Xuan Y.T., Tang X.L., Bao W., Wu W.J., Han H., Laubach V.E., Ping P., Yang Z., Qiu Y., and Bolli R. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 96 (1999) 11507-11512
51. Guo Z.H., Jiang H.Y., Xu X.R., Duan W.Z., and Mattson M.P. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J Biol Chem 283 (2008) 1754-1763
52. Gurniak C.B., and Berg L.J. Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 87 (1996) 3151-3160
53. Gwechenberger M., Mendoza L.H., Youker K.A., Frangogiannis N.G., Smith C.W., Michael L.H., and Entman M.L. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 99 (1999) 546-551
54. Halestrap A.P., Clarke S.J., and Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 1767 (2007) 1007-1031
55. Harada M., Qin Y.J., Takano H., Minamino T., Zou Y.Z., Toko H., Ohtsuka M., Matsuura K., Sano M., Nishi J., Iwanaga K., Akazawa H., Kunieda T., Zhu W.D., Hasegawa H., Kunisada K., Nagai T., Nakaya H., Yamauchi-Takihara K., and Komuro I. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11 (2005) 305-311
56. Haspel R.L., SaldittGeorgieff M., and Darnell J.E. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 15 (1996) 6262-6268
57. Hattori R., Maulik N., Otani H., Zhu L., Cordis G., Engelman R.M., Siddiqui M.A.Q., and Das D.K. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 33 (2001) 1929-1936
58. Hausenloy D.J., and Yellon D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70 (2006) 240-253
59. Hausenloy D.J., Maddock H.L., Baxter G.F., and Yellon D.M. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovasc Res 55 (2002) 534-543
60. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
61. Heinzel F.R., Luo Y., Li X., Boengler K., Buechert A., García-Dorado D., Di Lisa F., Schulz R., and Heusch G. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ Res 97 (2005) 583-586
62. Heusch G. Obesity-a risk factor or a RISK factor for myocardial infarction?. Br J Pharmacol 149 (2006) 1-3
63. Heusch G., Büchert A., Feldhaus S., and Schulz R. No loss of cardioprotection by postconditioning in connexin 43-deficient mice. Basic Res Cardiol 101 (2006) 354-356
64. Hilfiker-Kleiner D., Hilfiker A., Fuchs M., Kaminski K., Schaefer A., Schieffer B., Hillmer A., Schmiedl A., Ding Z., Podewski E., Poli V., Schneider M.D., Schulz R., Park J.K., Wollert K.C., and Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 95 (2004) 187-195
65. Hilfiker-Kleiner D., Hilfiker A., and Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Therapeut 107 (2005) 131-137
66. Hilfiker-Kleiner D., Kaminski K., Podewski E., Bonda T., Schaefer A., Sliwa K., Forster O., Quint A., Landmesser U., Doerries C., Luchtefeld M., Poli V., Schneider M.D., Balligand J.L., Desjardins F., Ansari A., Struman I., Nguyen N.Q., Zschemisch N.H., Klein G., Heusch G., Schulz R., Hilfiker A., and Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 (2007) 589-600
67. Hirota H., Yoshida K., Kishimoto T., and Taga T. Continuous activation of Gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92 (1995) 4862-4866
68. Hirota H., Chen J., Betz U.A.K., Rajewsky K., Gu Y., Ross J., Muller W., and Chien K.R. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97 (1999) 189-198
69. Hoey T., Zhang S.M., Schmidt N., Yu Q., Ramchandani S., Xu X., Naeger L.K., Sun Y.L., and Kaplan M.H. Distinct requirements for the naturally occurring splice forms Stat4 alpha and Stat4 beta in IL-12 responses. EMBO J 22 (2003) 4237-4248
70. Horvath C.M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 25 (2000) 496-502
71. Hsieh Y.J., Wakiyama H., Levitsky S., and McCully J.D. Cardioplegia and diazoxide modulate STAT3 activation and DNA binding. Ann Thorac Surg 84 (2007) 1272-1278
72. Huang C., Cao J., Huang K.J., Zhang F., Jiang T., Zhu L., and Qiu Z.J. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci 97 (2006) 1417-1423
73. Huffman L.C., Koch S.E., and Butler K.L. Coronary effluent from a preconditioned heart activates the JAK-STAT pathway and induces cardioprotection in a donor heart. Am J Physiol Heart Circ Physiol 294 (2008) H257-H262
74. Hwang Y.Y.C., Shaw S., Kaneko M., Redd H., Marrero M.B., and Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J 19 (2005) 795-797
75. Ishikawa M., Saito Y., Miyamoto Y., Harada M., Kuwahara K., Ogawa E., Nakagawa O., Hamanaka I., Kajiyama N., Takahashi N., Masuda I., Hashimoto T., Sakai O., Hosoya T., and Nakao K. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J Hypertens 17 (1999) 807-816
76. Jacoby J.J., Kalinowski A., Liu M.G., Zhang S.S.M., Gao Q., Chai G.X., Ji L., Iwamoto Y., Li E., Schneider M., Russell K.S., and Fu X.Y. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure-with advanced age. Proc Natl Acad Sci U S A 100 (2003) 12929-12934
77. Javadov S.A., Clarke S., Das M., Griffiths E.J., Lim K.H., and Halestrap A.P. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 549 (2003) 513-524
78. Jougasaki M., Tachibana I., Luchner A., Leskinen H., Redfield M.M., and Burnett J.C. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation 101 (2000) 14-17
79. Jougasaki M., Leskinen H., Larsen A.M., Cataliotti A., Chen H.H., and Burnett J.C. Leukemia inhibitory factor is augmented in the heart in experimental heart failure. Eur J Heart Fail 5 (2003) 137-145
80. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., Ziman B.D., Wang S., Ytrehus K., Antos C.L., Olson E.N., and Sollott S.J. Glycogen synthase kinase-3ß mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113 (2004) 1535-1549
81. Kaplan M.H., Sun Y.L., Hoey T., and Grusby M.J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382 (1996) 174-177
82. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 (2002) 1-24
83. Kodama H., Fukuda K., Pan J., Makino S., Sano M., Takahashi T., Hori S., and Ogawa S. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. Circ Res 82 (1998) 244-250
84. Kukielka G.L., Smith C.W., Manning A.M., Youker K.A., Michael L.H., and Entman M.L. Induction of interleukin-6 synthesis in the myocardium - potential role in postreperfusion inflammatory injury. Circulation 92 (1995) 1866-1875
85. Kunisada K., Tone E., Fujio Y., Matsui H., Yamauchi-Takihara K., and Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98 (1998) 346-352
86. Kuperman D., Schofield B., Wills-Karp M., and Grusby M.J. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 187 (1998) 939-948
87. Kurdi M., and Booz G.W. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling. J Cardiovasc Pharmacol 50 (2007) 126-141
88. Kuzuya T., Hoshida S., Yamashita N., Fuji H., Oe H., Hori M., Kamada T., and Tada M. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 72 (1993) 1293-1299
89. Kwon M.C., Koo B.K., Moon J.S., Kim Y.Y., Park K.C., Kim N.S., Kwon M.Y., Kong M.P., Yoon K.J., Im S.K., Ghim J., Han Y.M., Jang S.K., Shong M., and Kong Y.Y. Crif1 is a novel transcriptional coactivator of STAT3. EMBO J 27 (2008) 642-653
90. Lecour S., Suleman N., Deuchar G.A., Somers S., Lacerda L., Huisamen B., and Opie L.H. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112 (2005) 3911-3918
91. Levitzki A., and Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Ann Rev Biochem 75 (2006) 93-109
92. Leyva F., Anker S.D., Egerer K., Stevenson J.C., Kox W.J., and Coats A.J.S. Hyperleptinaemia in chronic heart failure - relationships with insulin. Eur Heart J 19 (1998) 1547-1551
93. Lim C.P., and Cao X.M. Structure, function, and regulation of STAT proteins. Mol Biosyst 2 (2006) 536-550
94. Lin Q., Lai R., Chirieac L.R., Li C.P., Thomazy V.A., Grammatikakis L., Rassidakis G.Z., Zhang W., Fujio Y., Kunisada K., Hamilton S.R., and Amin H.M. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines - inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167 (2005) 969-980
95. Liu X., Robinson G.W., Wagner K.U., Garrett L., Wynshaw-Boris A., and Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11 (1997) 179-186
96. Lu Y., Zhou J., Xu C., Lin H., Xiao J., Wang Z., and Yang B. JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 21 (2008) 305-314
97. Maher F.O., Nolan Y., and Lynch M.A. Downregulation of IL-4-induced signalling in hippocampus contributes to deficits in LTP in the aged rat. Neurobiol Aging 26 (2005) 717-728
98. Manginas A., Bei E., Chaidaroglou A., Degiannis D., Koniavitou K., Voudris V., Pavlides G., Panagiotakos D., and Cokkinos D.V. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 28 (2005) 182-186
99. Marber M.S., Latchman D.S., Walker J.M., and Yellon D.M. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88 (1993) 1264-1272
100. Maritano D., Sugrue M.L., Tininini S., Dewilde S., Strobl B., Fu X.P., Murray-Tait V., Chiarle R., and Poli V. The STAT3 isoforms and have unique and specific functions. Nat Immunol 5 (2004) 401-409
101. Mascareno E., Dhar M., and Siddiqui M.A.Q. Signal transduction and activator of transcription (STAT) protein-dependent activation of angiotensinogen promotor: a cellular signal for hypertrophy in cardiac muscle. Proc Natl Acad Sci U S A 95 (1998) 5590-5594
102. Mascareno E., El-Shafei M., Maulik N., Sato M., Guo Y., Das D.K., and Siddiqui M.A.Q. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 104 (2001) 325-329
103. Matsuyama N., Leavens J.E., McKinnon D., Gaudette G.R., Aksehirli T.O., and Krukenkamp I.B. Ischemic but not pharmacological preconditioning requires protein synthesis. Circulation 102 (2000) III312-III318
104. McCormick J., Barry S.P., Sivarajah A., Stefanutti G., Townsend P.A., Lawrence K.M., Eaton S., Knight R.A., Thiemermann C., Latchman D.S., and Stephanou A. Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. FASEB J 20 (2006) 2115-2117
105. McWhinney C.D., Dostal D., and Baker K. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes. J Mol Cell Cardiol 30 (1998) 751-761
106. Meraz M.A., White J.M., Sheehan K.C.F., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., CarverMoore K., Dubois R.N., Clark R., Aguet M., and Schreiber R.D. Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84 (1996) 431-442
107. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A., and Roifman C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379 (1996) 645-648
108. Moriggl R., Topham D.J., Teglund S., Sexl V., Mckay C., Wang D., Hoffmeyer A., van Deursen J., Sangster M.Y., Bunting K.D., Grosveld G.C., and Ihle J.N. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10 (1999) 249-259
109. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94 (2004) 7-16
110. Murphy E., and Steenbergen C. Preconditioning: the mitochondrial connection. Annu Rev Physiol 69 (2007) 51-67
111. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
112. Negoro S., Kunisada K., Tone E., Funamoto M., Oh H., Kishimoto T., and Yamauchi-Takihara K. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47 (2000) 797-805
113. Negoro S., Kunisada K., Fujio Y., Funamoto M., Darville M.I., Eizirik D.L., Osugi T., Izumi M., Oshima Y., Nakaoka Y., Hirota H., Kishimoto T., and Yamauchi-Takihara K. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104 (2001) 979-981
114. Ng D.C., Court N.W., dos Remedios C.G., and Bogoyevitch M.A. Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts. Cardiovasc Res 57 (2003) 333-346
115. Nicolosi A.C., Strande J.L., Hsu A., Fu X., Su J., Gross G.J., and Baker J.E. Gadolinium limits myocardial infarction in the rat: dose-response, temporal relations and mechanisms. J Mol Cell Cardiol 44 (2008) 345-351
116. O'Shea J.J., Gadina M., and Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 (2002) S121-S131
117. Olson E.N. A decade of discoveries in cardiac biology. Nat Med 10 (2004) 467-474
118. Omura T., Yoshiyama M., Ishikura F., Kobayashi H., Takeuchi K., Beppu S., and Yoshikawa J. Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J Mol Cell Cardiol 33 (2001) 307-316
119. Orus J., Roig E., Perez-Villa F., Pare C., Azqueta M., Filella X., Heras M., and Sanz G. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 19 (2000) 419-425
120. Oshima Y., Fujio Y., Akanishi T., Itoh N., Mamoto Y., Goro S., Naka K., Shimoto T., Wase I., and Uma J. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 65 (2005) 428-435
121. Osugi T., Oshima Y., Fujio Y., Funamoto M., Yamashita A., Negoro S., Kunisada K., Izumi M., Nakaoka Y., Hirota H., Okabe M., Yamauchi-Takihara K., Kawase I., and Kishimoto T. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 277 (2002) 6676-6681
122. Pacher P., and Hajnoczky G. Propagation of the apoptotic signal by mitochondrial waves. EMBO J 20 (2001) 4107-4121
123. ATP channels triggers the preconditioned state by generating free radicals. Circ Res 87 (2000) 460-466
124. Pan J., Fukuda K., Saito M., Matsuzaki J., Kodama H., Sano M., Takahashi T., Kato T., and Ogawa S. Mechanical stretch activates the JAK STAT pathway in rat cardiomyocytes. Circ Res 84 (1999) 1127-1136
125. Park C., Li S., Cha E., and Schindler C. Immune response in Stat2 knockout mice. Immunity 13 (2000) 795-804
126. Parsa C.J., Kim J., Riel R.U., Pascal L.S., Thompson R.B., Petrofski J.A., Matsumoto A., Stamler J.S., and Koch W.J. Cardioprotective effects of erythropoietin in the reperfused ischemic heart - a potential role for cardiac fibroblasts. J Biol Chem 279 (2004) 20655-20662
127. Petersen A.M., and Pedersen B.K. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57 (2006) 43-51
128. Podewski E.K., Hilfiker-Kleiner D., Hilfiker A., Morawietz H., Lichtenberg A., Wollert K.C., and Drexler H. Alterations in janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 107 (2003) 798-802
129. Potla R., Koeck T., Wegrzyn J., Cherukuri S., Shimoda K., Baker D.P., Wolfman J., Planchon S.M., Esposito C., Hoit B., Dulak J., Wolfman A., Stuehr D., and Larner A.C. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol 26 (2006) 8562-8571
130. Qian J.Y., Harding P., Liu Y.H., Shesely E., Yang X.P., and LaPointe M.C. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction. Hypertension 51 (2008) 560-566
131. Rafiee P., Shi Y., Su J., and Pritchard K.A. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100 (2005) 187-197
132. Railson J.E., Liao Z.H., Brar B.K., Buddle J.C., Pennica D., Stephanou A., and Latchman D.S. Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine 17 (2002) 243-253
133. Rajapurohitam V., Gan X.T., Kirshenbaum L.A., and Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 93 (2003) 277-279
134. Raju S.V.Y., Zheng M., Schuleri K.H., Phan A.C., Bedja D., Saraiva R.M., Yiginer O., Vandegaer K., Gabrielson K.L., O'Donnell C.P., Berkowitz D.E., Barouch L.A., and Hare J.M. Activation of the cardiac ciliary neurotrophic factor receptor reverses left ventricular hypertrophy in leptin-deficient and leptin-resistant obesity. Proc Natl Acad Sci U S A 103 (2006) 4222-4227
135. Rattazzi M., Puato M., Faggin E., Bertipaglia B., Zambon A., and Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. J Hypertens 21 (2003) 1787-1803
136. Rowland R.T., Meng X., Cleveland Jr. J.C., Meldrum D.R., Harken A.H., and Brown J.M. Cardioadaptation induced by cyclic ischemic preconditioning is mediated by translational regulation of de novo protein synthesis. J Surg Res 71 (1997) 155-160
137. Schaefer T.S., Sanders L.K., and Nathans D. Cooperative transcriptional activity of Jun and Stat3-Beta, a short-form of Stat3. Proc Natl Acad Sci U S A 92 (1995) 9097-9101
138. Schaefer T.S., Sanders L.K., Park O.K., and Nathans D. Functional differences between Stat3 alpha and Stat3 beta. Mol Cell Biol 17 (1997) 5307-5316
139. Schindler C., Fu X.Y., Improta T., Aebersold R., and Darnell J.E. Proteins of transcription factor Isgf-3 - one gene encodes the 91-kda and 84-kda Isgf-3 proteins that are activated by interferon-alpha. Proc Natl Acad Sci U S A 89 (1992) 7836-7839
140. Schulz R., Cohen M.V., Behrends M., Downey J.M., and Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res 52 (2001) 181-198
141. Serrano A.L., Baeza-Raja B., Perdiguero E., Jardi M., and Munoz-Cinoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 7 (2008) 33-44
142. Shi Y., Rafiee P., Su J., Pritchard K.A., Tweddell J.S., and Baker J.E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 99 (2004) 173-182
143. Shu J., Ren N., Du J.B., Zhang M., Cong H.L., and Huang T.G. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scand Cardiovasc J 41 (2007) 149-154
144. Singh K., Balligand J.L., Fischer T.A., Smith T.W., and Kelly R.A. Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells - role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha. J Biol Chem 271 (1996) 1111-1117
145. Smart N., Mojet M.H., Latchman D.S., Marber M.S., Duchen M.R., and Heads R.J. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 69 (2006) 164-177
146. Smith R.M., Suleman N., Lacerda L., Opie L.H., Akira S., Chien K.R., and Sack M.N. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 63 (2004) 611-616
147. Snyder M., Huang X.Y., and Zhang J.J.L. Identification of novel direct Stat3 target genes for control of growth and differentiation. J Biol Chem 283 (2008) 3791-3798
148. Soond S.M., Townsend P.A., Barry S.P., Knight R.A., Latchman D.S., and Stephanou A. ERK and the F-box protein beta TRCP target STAT1 for degradation. J Biol Chem 283 (2008) 16077-16083
149. Staat P., Rioufol G., Piot C., Cottin Y., Cung T.T., L'Huillier I., Aupetit J.F., Bonnefoy E., Finet G., Andre-Fouet X., and Ovize M. Postconditioning the human heart. Circulation 112 (2005) 2143-2148
150. Stephanou A., and Latchman D.S. Opposing actions of STAT-1 and STAT-3. Growth Factors 23 (2005) 177-182
151. Stephanou A., Brar B.K., Knight R.A., and Latchman D.S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7 (2000) 329-330
152. Stephanou A., Brar B.K., Scarabelli T.M., Jonassen A.K., Yellon D.M., Marber M.S., Knight R.A., and Latchmann D.S. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem 14 (2000) 10002-10008
153. Stephanou A., Scarabelli T.M., Brar B.K., Nakanishi Y., Matsumura M., Knight R.A., and Latchman D.S. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol Chem 276 (2001) 28340-28347
154. Stephanou A., Scarabelli T.M., Townsend P.A., Bell R., Yellon D., Knight R.A., and Latchman D.S. The carboxyl-terminal activation domain of the STAT-1 transcription factor enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes. FASEB J 16 (2002) 1841-1843
155. Suleman N., Somers S., Smith R., Opie L.H., and Lecour S.C. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 79 (2008) 127-133
156. Sun X., Zhang J., Wang L., and Tian Z. Growth inhibition of human hepatocullular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262 (2008) 201-213
157. Takahashi N., Saito Y., Kuwahara K., Harada M., Tanimoto K., Nakagawa Y., Kawakami R., Nakanishi M., Yasuno S., Usami S., Yoshimura A., and Nakao K. Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol 38 (2005) 185-192
158. Takano H., Manchikalapudi S., Tang X.L., Qiu Y., Rizvi A., Jadoon A.K., Zhang Q., and Bolli R. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 98 (1998) 441-449
159. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., Kishimoto T., and Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94 (1997) 3801-3804
160. Tatsumi T., Matoba S., Kawahara A., Keira N., Shiraishi J., Akashi K., Kobara M., Tanaka T., Katamura M., Nakagawa C., Ohta B., Shirayama T., Takeda K., Asayama J., Fliss H., and Nakagawa M. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 35 (2000) 1338-1346
161. Teglund S., Mckay C., Schuetz E., van Deursen J.M., Stravopodis D., Wang D.M., Brown M., Bodner S., Grosveld G., and Ihle J.N. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93 (1998) 841-850
162. Terrell A.M., Crisostomo P.R., Wairiuko G.M., Wang M., Morrell E.D., and Meldrum D.R. JAK/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. Shock 26 (2006) 226-234
163. Thibault H., Piot C., Staat P., Bontemps L., Sportouch C., Rioufol G., Tri Cung T., Bonnefoy E., Angoulvant D., Aupetit J.F., Finet G., Andre-Fouet X., Macia C., Raczeka F., Rossi R., Itti R., Kirkorian G., Derumeaux G., and Ovize M. Long term benefit of postconditioning. Circulation 117 (2008) 1037-1044
164. Thierfelder W.E., vanDeursen J.M., Yamamoto K., Tripp R.A., Sarawar S.R., Carson R.T., Sangster M.Y., Vignali D.A.A., Doherty P.C., Grosveld G.C., and Ihle J.N. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382 (1996) 171-174
165. Thornton J., Striplin S., Liu G.S., Swafford A., Stanley A.W.H., van Winkle D.M., and Downey J.M. Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning. Am J Physiol Heart Circ Physiol 259 (1990) H1822-H1825
166. Tone E., Kunisada K., Fujio Y., Matsui H., Negoro S., Oh H., Kishimoto T., and Yamauchi-Takihara K. Angiotensin II interferes with leukemia inhibitory factor-induced STAT3 activation in cardiac myocytes. Biochem Biophys Res Comm 253 (1998) 147-150
167. Townsend P.A., Scarabelli T.M., Davidson S.M., Knight R.A., Latchman D.S., and Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279 (2004) 5811-5820
168. Townsend P.A., Scarabelli T.M., Pasini E., Gitti G., Menegazzi M., Suzuki H., Knight R.A., Latchman D.S., and Stephanou A. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J 18 (2004) 1621-1623
169. Toyonaga T., Nakano K., Nagano M., Zhao G., Yamaguchi K., Kuroki S., Eguchi T., Chijiiwa K., Tsuneyoshi M., and Tanaka M. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 201 (2003) 107-116
170. Tsai C.T., Lai L.P., Kuo K.T., Hwang J.J., Hsieh C.S., Hsu K.L., Tseng C.D., Tseng Y.Z., Chiang F.T., and Lin J.L. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts - implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 117 (2008) 344-355
171. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., Mabuchi N., Sawaki M., and Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 391-398
172. Turkson J. STAT proteins as novel targets for cancer drug discovery. Exp Opin Therap Targ 8 (2004) 409-422
173. Turkson J., Bowman T., Adnane J., Zhang Y., Djeu J.Y., Sekharam M., Frank D.A., Holzman L.B., Wu J., Sebti S., and Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 19 (1999) 7519-7528
174. Udy G.B., Towers R.P., Snell R.G., Wilkins R.J., Park S.H., Ram P.A., Waxman D.J., and Davey H.W. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 94 (1997) 7239-7244
175. Ueda K., Takano H., Hasegawa H., Niitsuma Y., Qin Y., Ohtsuka M., and Komuro I. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 26 (2006) E108-E113
176. Uozumi H., Hiroi Y., Zou Y.Z., Takimoto E., Toko H., Niu P., Shimoyama M., Yazaki Y., Nagai R., and Komuro I. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 276 (2001) 23115-23119
177. Vinten-Johansen J. Postconditioning: a mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion. Heart Fail Rev 12 (2007) 235-244
178. Wang D.M., Stravopodis D., Teglund S., Kitazawa J., and Ihle J.N. Naturally occurring dominant negative variants of Stat5. Mol Cell Biol 16 (1996) 6141-6148
179. Wang F., Seta Y., Baumgarten G., Engel D.J., Sivasubramanian N., and Mann D.L. Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. Circulation 103 (2001) 1296-1302
180. Wang F., Trial J., Diwan A., Gao F., Birdsall H.H., Entman M.L., Hornsby P.J., Sivasubramaniam N., and Mann D.L. Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol 34 (2002) 1309-1316
181. Wang Z.Y., Jiang B.B., and Brecher P. Selective inhibition of STAT3 phosphorylation by sodium salicylate in cardiac fibroblasts. Biochem Pharmacol 63 (2002) 1197-1207
182. Wang R., Cherukuri P., and Luo J.Y. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 280 (2005) 11528-11534
183. Wang X.D., Chen X.M., Wang J.Z., Hong Q., Feng Z., Fu B., Zhou F., Wang F.Y., and Fan D.M. Signal transducers and activators of transcription 3 mediates up-regulation of angiotensin II-induced tissue inhibitor of metalloproteinase-1 expression in cultured human senescent fibroblasts. Chin Med J 119 (2006) 1094-1102
184. Wang M.J., Zhang W.J., Crisostomo P., Markel T., Meldrum K.K., Fu X.Y., and Meldrum D.R. Endothelial STAT3 plays a critical role in generalized myocardial proinflammatory and proapoptotic signaling. Am J Physiol Heart Circ Physiol 293 (2007) H2101-H2108
185. Wollert K.C., Taga T., Saito M., Narazaki M., Kishimoto T., Glembotski C.C., Vernallis A.B., Heath J.K., Pennica D., Wood W.I., and Chien K.R. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy - assembly of sarcomeric units in series via gp130 leukemia inhibitory factor receptor-dependent pathways. J Biol Chem 271 (1996) 9535-9545
186. Wu L., Zhao L., Zheng Q., Shang F., Wang X., Wang L., and Lang B. Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK/STAT pathway in cultured cardiomyocytes. Mol Cell Biochem 284 (2006) 65-71
187. Xi S.C., Gooding W.E., and Grandis J.R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24 (2005) 970-979
188. Xuan Y.T., Guo Y., Han H., Zhu Y., and Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A 98 (2001) 9050-9055
189. Xuan Y.T., Guo Y., Zhu Y., Wang O.L., Rokosh G., and Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 116 (2007) 535-544
190. Yamauchi-Takihara K., Ihara Y., Ogata A., Yoshizaki K., Azuma J., and Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 91 (1995) 1520-1524
191. Yamaura G., Turoczi T., Yamamoto F., Siddqui M.A.Q., Maulik N., and Das D.K. STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning. Am J Physiol Heart Circ Physiol 285 (2003) H476-H482
192. Yasukawa H., Hoshijima M., Gu Y.S., Nakamura T., Pradervand S., Hanada T., Hanakawa Y., Yoshimura A., Ross J., and Chien K.R. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 108 (2001) 1459-1467
193. Yellon D.M., and Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83 (2003) 1113-1151
194. Yoon P., Keylock K.T., Hartman M.E., Freund G.G., and Woods J.A. Macrophage hypo-responsiveness to interferon-gamma in aged mice is associated with impaired signaling through Jak-STAT. Mech Ageing Dev 125 (2004) 137-143
195. Yu X.W., Kennedy R.H., and Liu S.J. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem 278 (2003) 16304-16309
196. Zakharova N., Lymar E.S., Yang E., Malik S., Zhang J.J.L., Roeder R.G., and Darnell J.E. Distinct transcriptional activation functions of STAT1 alpha and STAT1 beta on DNA and chromatin templates. J Biol Chem 278 (2003) 43067-43073
197. Zhang X., Zhang J., Wei H., and Tian Z. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17 (2007) 1377-1382
198. Zhao Z.Q., and Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 55 (2002) 438-455
199. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., and Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285 (2003) H579-H588
200. Zou Y.Z., Takano H., Mizukami M., Akazawa H., Qin Y.J., Toko H., Sakamoto M., Minamino T., Nagai T., and Komuro I. Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 108 (2003) 748-753
201. Zurney J., Howard K.E., and Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol 81 (2007) 13668-13680